中国五个县扩大免疫规划实施前后儿童风疹抗体水平研究

发布时间：2018-05-08 13:08

本文选题：风疹疫苗 + 抗体　；参考：《中国疫苗和免疫》2017年02期

【摘要】：目的了解中国五个县扩大免疫规划实施前后儿童风疹抗体水平变化,为完善中国风疹疫苗免疫策略提供依据。方法在中国5个县抽取2001年、2005年和2009年出生的健康常住儿童进行风疹血清流行病学调查,采用酶联免疫吸附试验检测风疹IgG抗体,分析抗体阳性率、几何平均浓度(GMC)及其影响因素。结果共调查452名儿童,2001年、2005年和2009年出生儿童的风疹IgG抗体阳性率分别为94.56%、93.42%、94.12%(χ~2=0.18,P=0.916),GMC分别为135.02IU/ml、116.32IU/ml、139.92IU/ml(F=2.34,P=0.097)。儿童风疹抗体阳性率和抗体GMC随含风疹成分疫苗(RCV)接种剂次数而显著升高。随着采血时间与RCV接种时间间隔的增大,风疹抗体阳性率无显著下降,而GMC有显著下降,但大于20IU/ml。结论中国五个县扩大免疫规划实施前后儿童风疹抗体水平无显著变化,接种RCV是维持儿童风疹抗体高水平的重要因素,需继续巩固现行RCV免疫策略。
[Abstract]:Objective to investigate the changes of rubella antibody level in children before and after the implementation of expanded immunization program in five counties of China, and to provide evidence for improving the immunization strategy of rubella vaccine in China. Methods A seroepidemiological survey of rubella was carried out among healthy resident children born in 2001, 2005 and 2009 in five counties of China. Elisa was used to detect rubella IgG antibody, and the positive rate of rubella antibody was analyzed. Geometric mean concentration (GMC) and its influencing factors. Results the positive rates of rubella IgG antibody in children born in 2001, 2005 and 2009 were 94.56 and 93.42 respectively. The positive rate of rubella antibody and GMC increased significantly with the times of rubella vaccine inoculation. With the increase of the interval between blood collection time and RCV inoculation time, the positive rate of rubella antibody did not decrease significantly, but that of GMC decreased significantly, but more than 20 RCV / ml. Conclusion there is no significant change in rubella antibody level in children before and after the implementation of expanded immunization program in five counties in China. Inoculation with RCV is an important factor to maintain the high level of rubella antibody in children. It is necessary to continue to consolidate the current RCV immunization strategy.
【作者单位】：中国疾病预防控制中心免疫规划中心;哈尔滨医科大学;广东省疾病预防控制中心;上海市疾病预防控制中心;江苏省疾病预防控制中心;甘肃省疾病预防控制中心;
【基金】：十二五国家科技重大专项课题“传染病疫苗临床试验评价体系”(课题编号2012ZX10004703)
【分类号】：R186

【相似文献】